Oxford Drug Design raises 2 2.2 million to develop AI-based drug detection program
Biotechnology company Oxford Drug Design Limited: (ODD) has raised 2, 2.2 million in funding from existing investors, ACF Investors, o2h Ventures, Meltwind Advisory, several returning angels, new investors, and the US-based R42 Group.
The University of Oxford has developed its own artificial intelligence (AI) drug discovery platform focused on therapeutic needs in oncology.
Alan D. Roth, CEO of ODD, said: “This latest funding will enable us to build and accelerate the focus of our inventions based on our successful computing design. “We are excited to play a key role in innovation in cancer treatment that will lead to better outcomes for cancer patients worldwide.”
Rune Labs launches Portuguese subsidiary to improve diabetes care
Precision Neurology Software և Data Platform Company Runa Laboratories announced the creation of a team of leading designers based in Lisbon, Portugal.
The new team will focus on expanding Rune Labs functions և workflows. StrivePD: Parkinson’s treatment ecosystem. The subsidiary will also be Rune’s first permanent presence in Europe.
Rune Labs Vice President of Products Will Newby said: “Rune Labs is focused on providing people-centered care for people with Parkinson’s disease. Եւ The Portuguese team of product designers will ensure that patients, doctors and researchers have a voice in us. goods”.
Babylon GP at Hand opens two new clinics in London
Babylon GP at Hand has opened two new clinics in London that will provide patients with face-to-face appointments with its first digital integrated care.
The first clinic on Dean Farra Street, Victoria, opened last week, and next month the clinic will be on Drummond Street in Houston.
Dr. Matthew Noble, Medical Director of Babylon, UK, said: “Personal care is very important alongside highly available digital appointments. We are really excited to open these two new clinics for our Babylon GP in London.”
CDP Venture Capital launches digital startup accelerator
CDP Venture Capital Sgr: Announces the launch of digital healthcare startup accelerators focusing on innovative solutions for respiratory diseases, ophthalmology, women’s health, rare diseases, and chronic pain management.
The VITA program was created in conjunction with Healthware Group և’s Danish Accelerace Accelerator with total managed assets of € 6.35 million.
“VITA Accelerator demonstrates Healthware’s commitment to promoting digital health by supporting the growth and development of the most promising startups.”
Applications are open until June 12 for Italian startups և international startups planning to set up offices in Italy.
Clinical trials show blood test can detect 79% of early-stage bowel cancer
A clinical trial of primary care in West Wales has shown that a blood test can detect 79% of early-stage bowel cancer and 100% of advanced bowel cancer.
The Raman Spectrometry (RS) blood test was developed by Swansea University spin-out CanSense:Funded by Cancer Research Wales և Health and Care Research Wales.
CanSense also provided միլիոն 1.2 million from the National Institutes of Health (NIHR) to further develop the blood test for clinical use in Wales.
Dr. Seris Jenkins, co-founder and CEO of CanSense, said: “This test will be available in the triage phase, it will save time, money, but most importantly, it will save patients from anxiety, unnecessary diagnostic tests.”
AI Cancer Diagnosis Company has been awarded the Life Science Innovation Award
British AI startup Behold.AI has been awarded the Prix Galien Award for Best Digital Health Solution in the UK.
The company was awarded for its red dot® clinical analysis software to detect lung cancer from X-rays, which is used in several NHS hospitals as part of an independent validation of patient data.
Behold.AI CEO Ռ President Simon Rasalingham said: “Evidence from our expertise shows that if we implement this technology nationally, we can increase the equivalent of 233 NHS consultant radiologists to 255,000. annual consultant hours. ”
see secret product in Box below
‘The accuracy or reliability of any information/material/calculation contained in this article is not guaranteed. This information has been brought to you by collecting from various mediums / astrologers / almanacs / discourses / beliefs / scriptures. Our purpose is only to deliver information, its users should take it as mere information. In addition, any use thereof shall be the responsibility of the user himself.’